233 related articles for article (PubMed ID: 28600302)
1. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
Agraval U; Sobti M; Russell HC; Lockington D; Ritchie D; Cauchi P; Kemp EG; Chadha V
Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
3. Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.
Tsimpida M; Hungerford J; Arora A; Cohen V
Eye (Lond); 2011 Dec; 25(12):1607-11. PubMed ID: 21941358
[TBL] [Abstract][Full Text] [Related]
4. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients - the Tuebingen experience.
Süsskind D; Dürr C; Paulsen F; Kaulich T; Bartz-Schmidt KU
Acta Ophthalmol; 2017 Dec; 95(8):e727-e733. PubMed ID: 27914117
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium-106 plaque brachytherapy for uveal melanoma.
Tarmann L; Wackernagel W; Avian A; Mayer C; Schneider M; Winkler P; Langmann G
Br J Ophthalmol; 2015 Dec; 99(12):1644-9. PubMed ID: 25979763
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
[TBL] [Abstract][Full Text] [Related]
7. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma.
Marconi DG; de Castro DG; Rebouças LM; Bernardes Gil GO; Fogaroli RC; Conte Maia MA; Gobo Silva ML; Assis Pellizzon AC; Motono Chojniak MM
Brachytherapy; 2013; 12(3):235-9. PubMed ID: 22436517
[TBL] [Abstract][Full Text] [Related]
8. Regression Patterns of Iris Melanoma after Palladium-103 (
Chaugule SS; Finger PT
Ophthalmology; 2017 Jul; 124(7):1023-1030. PubMed ID: 28377036
[TBL] [Abstract][Full Text] [Related]
9. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
Perri P; Fiorica F; D'Angelo S; Lamberti G; Parmeggiani F; Martini A; Carpenteri F; Colosimo C; Micucci M; Perazzini L; De Gugliemo E; Berretta M; Sebastiani A; Cartei F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
12. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
Barker CA; Francis JH; Cohen GN; Marr BP; Wolden SL; McCormick B; Abramson DH
Brachytherapy; 2014; 13(6):584-90. PubMed ID: 24880583
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
Razzaq L; de Keizer RJ
Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
[No Abstract] [Full Text] [Related]
14. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma.
Verschueren KM; Creutzberg CL; Schalij-Delfos NE; Ketelaars M; Klijsen FL; Haeseker BI; Ligtenberg SM; Keunen JE; Marijnen CA
Radiother Oncol; 2010 Jun; 95(3):332-8. PubMed ID: 20416963
[TBL] [Abstract][Full Text] [Related]
15. Management of iris melanomas with 125Iodine plaque radiotherapy.
Fernandes BF; Krema H; Fulda E; Pavlin CJ; Payne DG; McGowan HD; Simpson ER
Am J Ophthalmol; 2010 Jan; 149(1):70-6. PubMed ID: 19892312
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective analysis of ruthenium-106 brachytherapy for small and medium-sized malignant melanoma of the posterior choroid].
Stoffelns BM; Kutzner J; Jochem T
Klin Monbl Augenheilkd; 2002 Apr; 219(4):216-20. PubMed ID: 12022004
[TBL] [Abstract][Full Text] [Related]
17. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
[TBL] [Abstract][Full Text] [Related]
18. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience.
Seregard S; aft Trampe E; Lax I; Kock E; Lundell G
Acta Ophthalmol Scand; 1997 Feb; 75(1):11-6. PubMed ID: 9088393
[TBL] [Abstract][Full Text] [Related]
19. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.
Espensen CA; Appelt AL; Fog LS; Thariat J; Gothelf AB; Aznar MC; Kiilgaard JF
Acta Oncol; 2020 Aug; 59(8):918-925. PubMed ID: 32412331
[No Abstract] [Full Text] [Related]
20. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981-1989.
Pötter R; Janssen K; Prott FJ; Widder J; Haverkamp U; Busse H; Müller RP
Front Radiat Ther Oncol; 1997; 30():143-9. PubMed ID: 9205894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
